Edition:
United Kingdom

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

13.13USD
23 May 2018
Change (% chg)

$0.68 (+5.46%)
Prev Close
$12.45
Open
$12.32
Day's High
$13.16
Day's Low
$12.32
Volume
71,359
Avg. Vol
135,823
52-wk High
$14.62
52-wk Low
$4.29

Latest Key Developments (Source: Significant Developments)

Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Adaptimmune Therapeutics Plc ::ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING.ADAPTIMMUNE THERAPEUTICS - AGREEMENT IS FOR TERM OF 5 YEARS WITH EARLIER TERMINATION AVAILABLE TO BOTH PARTIES ON PROVISION OF 12 MONTHS' NOTICE.ADAPTIMMUNE THERAPEUTICS PLC - AGREEMENT WILL ENABLE CO TO HAVE ITS OWN DEDICATED VECTOR MANUFACTURING SPACE IN UK.ADAPTIMMUNE - AGREEMENT TO ENSURE VECTOR SUPPLY PRODUCTION BEYOND 2020 FOR ONGOING STUDIES WITH 3 SPEAR T-CELL THERAPIES, MAGE-A4, MAGE-A10 AND AFP.  Full Article

Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Adaptimmune Therapeutics Plc :::ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE.ADAPTIMMUNE THERAPEUTICS PLC - NO EVIDENCE OF TOXICITY RELATED TO OFF-TARGET BINDING OR ALLOREACTIVITY HAS BEEN OBSERVED.ADAPTIMMUNE - IN NSCLC STUDY, THERE HAS BEEN ONE SERIOUS ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME, A GRADE 4 EVENT THAT RESOLVED WITH TREATMENT.ADAPTIMMUNE THERAPEUTICS PLC - ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME IN NSCLC STUDY LED TO COHORT 1 EXPANSION FROM 3 TO 6 PATIENTS.  Full Article

Adaptimmune Therapeutics Q3 loss per share $0.00
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune reports third quarter 2017 financial results and business updates.Q3 revenue $27.2 million versus $2.4 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.00.Adaptimmune- existing cash, cash equivalents, securities, income from GSK on transition of NY-ESO program to fund operating plan through to early 2020​.  Full Article

Adaptimmune Therapeutics reports Q2 loss per share $0.05
Monday, 8 Aug 2016 

Adaptimmune Therapeutics Plc : Adaptimmune reports second quarter 2016 financial results . Q2 revenue view $3.6 million -- Thomson Reuters I/B/E/S . Qtrly loss per share $0.05 . Adaptimmune is reiterating its guidance for 2016 .Q2 revenue $300,000 versus $2.8 million.  Full Article

Adaptimmune Q2 net loss per diluted ordinary share $0.05
Monday, 8 Aug 2016 

Adaptimmune Therapeutics Plc : Q2 revenue $300,000 versus $2.8 million . Adaptimmune reports second quarter 2016 financial results . Q2 revenue view $3.6 million -- Thomson Reuters I/B/E/S . Reiterating its FY 2016 guidance . Qtrly net loss per diluted ordinary share $0.05 .Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Adaptimmune announces partial clinical hold of planned pivotal study
Wednesday, 3 Aug 2016 

Adaptimmune Therapeutics Plc : Adaptimmune announces partial clinical hold of planned pivotal study of ny-eso spear® t-cell therapy in myxoid round cell liposarcoma . Trial is not yet active at any investigational sites, and has not recruited any patients . Notification of partial clinical hold does not apply to any other adaptimmune study . Fda notification is not based on safety concerns . Fda requested additional cmc information and answers to certain trial design questions prior to trial start .Notice from u.s. Fda that partial clinical hold placed on planned pivotal study of ny-eso spear t-cell therapy.  Full Article

Adaptimmune gets priority medicines regulatory support for its Spear T-cell therapy
Thursday, 28 Jul 2016 

Adaptimmune Therapeutics Plc :Adaptimmune receives access to priority medicines (PRIME) regulatory support for its Spear T-cell therapy targeting NY-ESO for treatment of soft tissue sarcoma.  Full Article

Adaptimmune Therapeutics receives positive opinion
Monday, 20 Jun 2016 

Adaptimmune Therapeutics Plc : Adaptimmune receives positive opinion for orphan drug designation in the European Union for spear t-cell therapy targeting NY-ESO for treatment of soft tissue sarcoma .Says expects to initiate pivotal studies in synovial sarcoma in 4Q16/1Q17.  Full Article

BRIEF-Adaptimmune Reports Q1 Loss Per Share $0.04

* ADAPTIMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE